Raltegravir Insulin Sensitivity Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

18 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-10-31

Study Completion Date

2008-08-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of the study is to look at the effects of two different HIV medications on the body's response to insulin (a hormone that regulates blood sugar levels). This will be done using a method called the 'euglycaemic clamp'

The study will also investigate the effects of these drugs on blood fats and on circulating markers in the blood stream related to blood vessels (vascular inflammation markers).

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics (PK) Study of Once Daily Darunavir/Ritonavir and Twice and Once Daily Raltegravir in HIV-infected Subjects

NCT01047995

HIV Infections

COMPLETED PHASE1

Effects of Raltegravir (Isentress®) on Lipid and Carbohydrate Metabolism and Mitochondrial Function in Healthy Volunteers

NCT00772720

Healthy Volunteers

UNKNOWN PHASE1

The Raltegravir and Ribavirin Pharmacokinetics (PK) Study

NCT00982553

HIV Infections

COMPLETED PHASE1

A Two Way Cross Over Pharmacokinetic Interaction Study Between Raltegravir and Amlodipine in Healthy Volunteers

NCT01841593

HIV

COMPLETED PHASE1

Buprenorphine/Raltegravir Pharmacokinetic Interaction Study

NCT00858962

HIV Infection HIV Infections

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Subjects will undergo four euglycaemic clamp procedures in order to determine the extent of glucose disposal. The first clamp will be performed prior to the commencement of the first study drug administration, the second one following two weeks of study drug, the third after a two week washout period, prior to commencement of second study drug administration and the fourth after two weeks of the second study drug

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

HIV Infections

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

Raltegravir 400 mg twice daily for the first 14 days of the study. Lopinavir/ritonavir 400/100 mg twice daily for the last 14 days of the study

Group Type ACTIVE_COMPARATOR

Raltegravir then lopinavir/ritonavir

Intervention Type DRUG

raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study

2

* Lopinavir/ritonavir 400/100 mg twice daily for the first 14 days of the study.
* Raltegravir 400 mg twice daily for the last 14 days of the study.

Group Type ACTIVE_COMPARATOR

Lopinavir/ritonavir then raltegravir

Intervention Type DRUG

lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Raltegravir then lopinavir/ritonavir

raltegravir 400mg twice daily for first 14 days of study lopinavir/ritonavir 400/100mg twice daily for last 14 days of study

Intervention Type DRUG

Lopinavir/ritonavir then raltegravir

lopinavir/ritonavir 400 mg twice daily for the first 14 days of the study raltegravir 400mg twice daily for the last 14 days of the study

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Subjects must have documented negative HIV serology by ELISA and P24 antigen
* Subjects must be clinically well males aged between 18 to 60 years
* Fasting blood glucose, total cholesterol and triglycerides within normal limits
* Hepatic transaminases (AST and ALT) ≤ 3 × upper limit of normal (ULN)
* Adequate hematologic function (absolute neutrophil count ≥ 1,000/mm3; platelets ≥ 50,000/mm3; hemoglobin ≥ 8.0 g/dL)
* Serum amylase ≤ 1.5 × ULN (subjects with serum amylase \> 1.5 × ULN will remain eligible if pancreatic lipase is ≤ 1.5 × ULN)
* Sexually active males must use condoms during the course of the study
* Life expectancy ≥ 1 year
* Willing and able to provide informed consent

Exclusion Criteria

* Subjects with a waist hip ratio \> 0.97 or BMI \> 28 kg/m2 will be excluded
* Acute or chronic hepatitis B infection (determined by positive hepatitis B surface antigen result at the screening visit)
* Acute or chronic hepatitis C infection (determined by positive hepatitis C antibody result at the screening visit)
* Other metabolic syndrome or disease process in the opinion of the investigator likely to cause marked disturbance in glucose and lipid homeostasis including hypertension
* Receiving on-going therapy with any of the following:

* Metabolically active medications
* Any lipid-lowering medication
* Hormonal agents (oestrogens or androgens)
* Glucocorticoids
* Beta-blockers
* Thiazide diuretics
* Thyroid preparations
* Psychotropic agents
* Anabolic steroids
* Megestrol acetate

Minimum Eligible Age

18 Years

Maximum Eligible Age

60 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes